| SEQ_NO | 1 | Date of announcement | 2025/05/15 | Time of announcement | 15:14:37 |
| Subject | The Company has been required by TPEx to announce the financial data according to the regulations. | ||||
| Date of events | 2025/05/15 | To which item it meets | paragraph 53 | ||
| Statement | 1.Date of occurrence of the event: 2025/05/15 2.Cause of occurrence:Announced as required by the TPEx 3.Financial and business information: Unit: (NT$million) (1) Monthly April 2025 April 2024 YoY Change % ————————————————————————— Sales revenue 35.914 20.738 73.18% Loss before income tax (64.912) (73.120) 11.23% Net Loss attributable to Owners of the parent (61.889) (62.427) 0.86 EPS (NT$) (0.67) (0.68) 1.47%(‘?l’?) =========================================================================== (2)Quarterly Q1 2025 Q1 2024 YoY Change % ————————————————————————— Sales revenue 101.878 47.141 116.11% Loss before income tax (190.856) (214.799) 11.15% Net Loss attributable to Owners of the parent (177.993) (199.827) 10.93% EPS (NT$) (1.93) (2.17) 11.06%(‘?l’?) =========================================================================== (3)Cumulative for the last four seasons Latest 4 quarters accumulation (Q2 2024 to Q2 2025) ————————————————————————— Revenue 347.545 Loss before income tax (834.700) Net Loss attributable to Owners of the parent (783.678) EPS (NT$) (8.50) =========================================================================== 4.Any material information that needs to be specified according to Article 4 of Taipei Exchange Procedures for Verification and Disclosure of Material Information of Companies with TPEx Listed Securities: On May 7, 2025, Medeon announced the content of material information press conference, disclosing the preliminary clinical results for the IDE Study in evaluating its BPH minimally invasive treatment device Urocross. 5.Any material information in a press conference listed under Article 11 of Taipei Exchange Procedures for Verification and Disclosure of Material Information of Companies with TPEx Listed Securities: On May 7, 2025, Medeon announced to host the material information press conference, disclosing the preliminary clinical results for the IDE Study in evaluating its BPH minimally invasive treatment device Urocross. 6.Any other matters that need to be specified: (1)The aforementioned financial information for April 2025 and its YOY comparison consists in the consolidated reviewed amounts prepared by the Company adopting the IFRS, and has not been audited (reviewed) by CPA; it is only for reference by investors. (2)The information for the latest quarter (Q1 2025) refers to single quarter amounts, not cumulative amounts from the latest financial reports, and are consolidated amounts prepared under the IFRS, which have been audited (reviewed) by CPA; it is only for reference by investors. (3)The information accumulated over the last 4 quarters consists in the consolidated amounts from Q2 2024 to Q1 2025 prepared by the Company adopting the IFRS, and has been audited (reviewed) by CPA; it is only for reference by investors. |
||||